School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China.
School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China.
Chin J Nat Med. 2024 Jul;22(7):582-598. doi: 10.1016/S1875-5364(24)60674-6.
Liver fibrosis is characterized by chronic inflammatory responses and progressive fibrous scar formation. Macrophages play a central role in the pathogenesis of hepatic fibrosis by reconstructing the immune microenvironment. Picroside II (PIC II), extracted from Picrorhizae Rhizoma, has demonstrated therapeutic potential for various liver damage. However, the mechanisms by which macrophage polarization initiates immune cascades and contributes to the development of liver fibrosis, and whether this process can be influenced by PIC II, remain unclear. In the current study, RNA sequencing and multiple molecular approaches were utilized to explore the underlying mechanisms of PIC II against liver fibrosis in multidrug-resistance protein 2 knockout (Mdr2) mice. Our findings indicate that PIC II activates M1-polarized macrophages to recruit natural killer cells (NK cells), potentially via the CXCL16-CXCR6 axis. Additionally, PIC II promotes the apoptosis of activated hepatic stellate cells (aHSCs) and enhances the cytotoxic effects of NK cells, while also reducing the formation of neutrophil extracellular traps (NETs). Notably, the anti-hepatic fibrosis effects associated with PIC II were largely reversed by macrophage depletion in Mdr2 mice. Collectively, our research suggests that PIC II is a potential candidate for halting the progression of liver fibrosis.
肝纤维化的特征是慢性炎症反应和进行性纤维瘢痕形成。巨噬细胞通过重构免疫微环境在肝纤维化的发病机制中起着核心作用。从獐牙菜中提取的獐牙菜苦苷(PIC II)已被证明对各种肝损伤具有治疗潜力。然而,巨噬细胞极化引发免疫级联反应并促进肝纤维化发展的机制,以及这一过程是否可以被 PIC II 影响,尚不清楚。在本研究中,利用 RNA 测序和多种分子方法探讨了 PIC II 在多药耐药蛋白 2 敲除(Mdr2)小鼠肝纤维化中的作用机制。我们的研究结果表明,PIC II 通过 CXCL16-CXCR6 轴激活 M1 极化的巨噬细胞募集自然杀伤细胞(NK 细胞)。此外,PIC II 促进活化的肝星状细胞(aHSCs)凋亡,并增强 NK 细胞的细胞毒性作用,同时减少中性粒细胞胞外诱捕网(NETs)的形成。值得注意的是,在 Mdr2 小鼠中,巨噬细胞耗竭使 PIC II 与肝纤维化相关的抗肝纤维化作用大部分逆转。综上所述,我们的研究表明 PIC II 可能是阻止肝纤维化进展的潜在候选药物。